Safety and effectiveness of rapid-acting intra-muscular olanzapine for agitation associated with schizophrenia – Japan postmarketing surveillance study

por Katagiri, Hideaki, Taketsuna, Masanori, Kondo, Shinpei, Kajimoto, Kenta, Aoi, Etsuko, Tanji, Yuka
Publicado 2018

Effectiveness and safety of oral olanzapine treatment transitioned from rapid-acting intramuscular olanzapine for agitation associated with schizophrenia

por Katagiri, Hideaki, Taketsuna, Masanori, Kondo, Shinpei, Kajimoto, Kenta, Aoi, Etsuko, Tanji, Yuka
Publicado 2018

Phase 2 randomized placebo‐controlled study of lasmiditan for the acute treatment of migraine in Japanese patients

por Sakai, Fumihiko, Takeshima, Takao, Homma, Gosuke, Tanji, Yuka, Katagiri, Hideaki, Komori, Mika
Publicado 2021

A randomized, double-blind, placebo-controlled study of rapid-acting intramuscular olanzapine in Japanese patients for schizophrenia with acute agitation

por Katagiri, Hideaki, Fujikoshi, Shinji, Suzuki, Takuya, Fujita, Kiyoshi, Sugiyama, Naoya, Takahashi, Michihiro, Gomez, Juan-Carlos
Publicado 2013

Erratum: A randomized, double-blind, placebo-controlled study of rapid-acting intramuscular olanzapine in Japanese patients for schizophrenia with acute agitation

por Katagiri, Hideaki, Fujikoshi, Shinji, Suzuki, Takuya, Fujita, Kiyoshi, Sugiyama, Naoya, Takahashi, Michihiro, Gomez, Juan-Carlos
Publicado 2014

Efficacy and safety of olanzapine for treatment of patients with bipolar depression: Japanese subpopulation analysis of a randomized, double-blind, placebo-controlled study

por Katagiri, Hideaki, Tohen, Mauricio, McDonnell, David P, Fujikoshi, Shinji, Case, Michael, Kanba, Shigenobu, Takahashi, Michihiro, Gomez, Juan-Carlos
Publicado 2013